ZGNX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States...

Stats
今日成交量	11.25M
平均成交量	3.10M
市值	0.00
EPS	$-0.980 ( 2022-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.603 (2.26%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-07	Breitmeyer James B	Sell	1 250	Common Stock
2022-03-07	Breitmeyer James B	Sell	9 375	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	6 250	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	9 000	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 \| Sell: 2 096 567

音量相关性

長: 0.49 (neutral)

短: 0.91 (very strong)

Signal:(77.726) Expect same movement, but be aware

Zogenix Inc 相关性

10 最正相关
BRACU	0.97
ATRS	0.969
ATCX	0.967
XLRN	0.957
CTSO	0.955
EYEN	0.952
ARAY	0.947
NVCN	0.946
ALGN	0.945
FOCS	0.945

10 最负相关
NAKD	-0.948
TRIT	-0.935
AHPI	-0.931
AMRB	-0.922
GRPH	-0.922
GRIN	-0.909
PROC	-0.907
CHKEL	-0.905
TUEM	-0.904
LAWS	-0.902

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Zogenix Inc 相关性 - 货币/商品

0.13
( neutral )

0.68
( moderate )

0.09
( neutral )

-0.01
( neutral )

-0.68
( moderate negative )

-0.82
( strong negative )

Zogenix Inc 财务报表

Annual	2021
营收:	$81.69M
毛利润:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2021
营收:	$81.69M
毛利润:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2020
营收:	$13.64M
毛利润:	$13.10M (96.03 %)
EPS:	$-3.90

FY	2019
营收:	$3.65M
毛利润:	$3.65M (100.00 %)
EPS:	$-9.74

Financial Reports:

No articles found.

Zogenix Inc

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.